Transfection of MS-36 melanoma cells with gef gene inhibits proliferation and induces modulation of the cell cycle

被引:12
作者
Boulaiz, H [1 ]
Prados, J
Marchal, JA
García, AM
Alvarez, L
Melguizo, C
Carrillo, E
Ramos, JL
Aránega, A
机构
[1] Univ Granada, Fac Med, Depto Ciencias Morfol, Secc Invest Basica Cardiovasc,Sch Med, E-18071 Granada, Spain
[2] Univ Jaen, Dept Hlth Sci, E-23071 Jaen, Spain
[3] Virgen Nieves Hosp, Clin Anal Serv, E-18014 Granada, Spain
[4] Univ Almeria, Dept Hlth Sci, E-04002 Almeria, Spain
[5] CSIC, Zaidin Expt Stn, E-18008 Granada, Spain
关键词
D O I
10.1111/j.1349-7006.2003.tb01483.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The gef gene, found in Escherichia coli DNA, encodes a small (50 amino acids) protein which is related to cell-killing functions. We used the MS-36 melanoma cell line as an experimental model to examine the usefulness of the gef gene as a new strategy for cancer therapy. We transfected MS-36 cells using the pMAMneo vector, and induced gef gene expression with dexamethasone. This decreased the proliferation rate of MS-36TG by as much as 85% in comparison with MS-36 parental cells. The decrease in cell growth was accompanied with significant modifications of the cell cycle and morphology. The G1-phase gradually disappeared, with accumulation in the S-phase. However, studies with annexin V-FITC and 7-aminoactinomycin D failed to demonstrate induction of apoptosis. Morphological changes were an increase in cell size and the number of filopodia, and especially the appearance of pore-like alterations in the cell membrane which were not seen in parental cells. Our results demonstrate that the gef gene, a system independent of the administration of a prodrug, significantly reduces the proliferation of MS-36 cells. This gene may therefore be considered a new candidate for cancer gene therapy.
引用
收藏
页码:564 / 568
页数:5
相关论文
共 32 条
[1]   In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors [J].
Crystal, RG .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 43 (Suppl 1) :S90-S99
[2]   Suicide gene therapy: possible applications in haematopoietic disorders [J].
Dilber, MS ;
Gahrton, G .
JOURNAL OF INTERNAL MEDICINE, 2001, 249 (04) :359-367
[3]  
Dong YB, 1999, CANCER, V86, P2021, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2021::AID-CNCR20>3.0.CO
[4]  
2-1
[5]   Suicide gene therapy using E-coli β-galactosidase [J].
Farquhar, D ;
Pan, BF ;
Sakurai, M ;
Ghosh, A ;
Mullen, CA ;
Nelson, JA .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 50 (01) :65-70
[6]  
Freeman SM, 2000, ADV EXP MED BIOL, V465, P411
[7]   MECHANISM OF POSTSEGREGATIONAL KILLING BY THE HOK GENE-PRODUCT OF THE PARB SYSTEM OF PLASMID R1 AND ITS HOMOLOGY WITH THE RELF GENE-PRODUCT OF THE ESCHERICHIA-COLI RELB OPERON [J].
GERDES, K ;
BECH, FW ;
JORGENSEN, ST ;
LOBNEROLESEN, A ;
RASMUSSEN, PB ;
ATLUNG, T ;
BOE, L ;
KARLSTROM, O ;
MOLIN, S ;
VONMEYENBURG, K .
EMBO JOURNAL, 1986, 5 (08) :2023-2029
[8]  
GERDES K, 1990, New Biologist, V2, P946
[9]  
Greco O, 2001, J CELL PHYSIOL, V187, P22, DOI 10.1002/1097-4652(2001)9999:9999<::AID-JCP1060>3.0.CO
[10]  
2-H